In vitro and in vivo pharmacological characterization of SB 201993, an eicosanoid-like LTB4 receptor antagonist with anti-inflammatory activity

被引:6
作者
Sarau, HM
Foley, JJ
Schmidt, DB
Martin, LD
Webb, EF
Tzimas, MN
Breton, JJ
Chabot-Fletcher, M
Underwood, DC
Hay, DWP
Kingsbury, WD
Chambers, PA
Pendrak, I
Jakas, DR
Sathe, GM
Van Horn, S
Daines, RA
Griswold, DE
机构
[1] SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA
[2] SmithKline Beecham Pharmaceut, Dept Immunol, King Of Prussia, PA 19406 USA
[3] SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA
[4] SmithKline Beecham Pharmaceut, Dept Genet Technol, King Of Prussia, PA 19406 USA
来源
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS | 1999年 / 61卷 / 01期
关键词
D O I
10.1054/plef.1999.0074
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Leukotriene B-4 (LTB4) and 12-(R)-hydroxy-5,8,10,14-eicosatetraenoic acid (12-[R]-HETE) have been postulated to contribute to the pathophysiology of inflammatory diseases. SE 201993, (E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4-methoxyphenyl)octyl] oxy]-2-pyridinyl] methyl] thio] methyl] benzoic acid, identified from a chemical series designed as ring-fused analogs of LTB4, was evaluated as an antagonist of LTB4- and 12-(R)-HETE-induced responses in vitro and for anti-inflammatory activity in vivo. SE 201993 competitively antagonized [(3)-H]-LTB4 binding to intact human neutrophils (K-i = 7.6 nM) and to membranes of RBL 2H3 cells expressing the LTB4 receptor (RBL 2H3-LTB4R; IC50 = 154 nM). This compound demonstrated competitive antagonism of LTB4- and 12-(R)-HETE-induced Ca2+ mobilization responses in human neutrophils (IC(50)s of 131 nM and 105 nM, respectively) and inhibited LTB4-induced Ca2+ mobilization in human cultured keratinocytes (IC50 = 61 nM), RBL 2H3-LTB4R cells (IC50 = 255 nM) and mouse neutrophils (IC50 = 410 nM). SE 201993 showed weak LTD4-receptor binding affinity (K-i = 1.9 mu M) and inhibited 5-lipoxygenase (IC50 of 3.6 mu M), both in vitro and ex vivo. In vivo, SE 201993 inhibited LTB4-induced neutrophil infiltration in mouse skin and produced dose-related, long lasting topical anti-inflammatory activity against the fluid and cellular phases of arachidonic acid-induced mouse ear inflammation (ED50 of 580 mu g/ear and 390 mu g/ear, respectively). Similarly, anti-inflammatory activity was also observed in the murine phorbol ester-induced cutaneous inflammation model (ED50 of 770 and 730 mu g/ear, respectively, against the fluid and cellular phases). These results indicate that SE 201993 blocks the actions of LTB4 and 12-(R)-HETE and inhibits a variety of inflammatory responses; and thus may be a useful compound to evaluate the role of these mediators in disease models.
引用
收藏
页码:55 / 64
页数:10
相关论文
共 47 条
[1]   HUMAN AT(1) RECEPTOR IS A SINGLE-COPY GENE - CHARACTERIZATION IN A STABLE CELL-LINE [J].
AIYAR, N ;
BAKER, E ;
WU, HL ;
NAMBI, P ;
EDWARDS, RM ;
TRILL, JJ ;
ELLIS, C ;
BERGSMA, DJ .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1994, 131 (01) :75-86
[2]   Molecular cloning of a novel P2 purinoceptor from human erythroleukemia cells [J].
Akbar, GKM ;
Dasari, VR ;
Webb, TE ;
Ayyanathan, K ;
Pillarisetti, K ;
Sandhu, AK ;
Athwal, RS ;
Daniel, JL ;
Ashby, B ;
Barnard, EA ;
Kunapuli, SP .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (31) :18363-18367
[3]   A 12R-lipoxygenase in human skin: Mechanistic evidence, molecular cloning, and expression [J].
Boeglin, WE ;
Kim, RB ;
Brash, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6744-6749
[4]  
Boyum A., 1968, SCAND J CLIN LAB INV, V21, P97
[5]   MEASUREMENT OF CUTANEOUS INFLAMMATION - ESTIMATION OF NEUTROPHIL CONTENT WITH AN ENZYME MARKER [J].
BRADLEY, PP ;
PRIEBAT, DA ;
CHRISTENSEN, RD ;
ROTHSTEIN, G .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1982, 78 (03) :206-209
[6]   LEUKOTRIENES IN INFLAMMATION [J].
BRAY, MA .
AGENTS AND ACTIONS, 1986, 19 (1-2) :87-99
[7]   Human keratinocytes lack the components to produce leukotriene B-4 [J].
Breton, J ;
Woolf, D ;
Young, P ;
ChabotFletcher, M .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1996, 106 (01) :162-167
[8]  
CHABOTFLETCHER MC, 1995, J PHARMACOL EXP THER, V273, P1147
[9]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[10]   (E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2-pyridinyl]-2-propenoic acid: A high-affinity leukotriene B-4 receptor antagonist with oral antiinflammatory activity [J].
Daines, RA ;
Chambers, PA ;
Foley, JJ ;
Griswold, DE ;
Kingsbury, WD ;
Martin, LD ;
Schmidt, DB ;
Sham, KKC ;
Sarau, HM .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (19) :3837-3841